This is a prospective open label study assessing the efficacy and tolerability of
pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric
patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of
anticonvulsant medication.
Phase:
Phase 4
Details
Lead Sponsor:
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.